Rivoceranib

Generic Name: Rivoceranib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₃N_₅O

CAS Number: 811803-05-1

Unique Ingredient Identifier: 5S371K6132

Background: Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).

Indication: 本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

First-line Treatment of Advanced/unresectable DDLPS

Phase 2

Not yet recruiting

Conditions: Dedifferentiated Liposarcoma
Soft Tissue Sarcoma (STS)

Interventions: Drug: Liposomal Doxorubicin (Doxil)
Drug: Apatinib
Drug: Camrelizumab

First Posted Date: 2024-11-19

Last Posted Date: 2024-11-19

Lead Sponsor: Fudan University

Target Recruit Count: 49

Registration Number: NCT06694324

Locations: 🇨🇳
Fudan University, Cancer Hospital, Shanghai, Shanghai, China

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Phase 2

Not yet recruiting

Conditions: Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions: Drug: Camrelizumab
Drug: Apatinib
Drug: S-1, Oxaliplatin

First Posted Date: 2024-11-18

Last Posted Date: 2024-11-18

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 80

Registration Number: NCT06693128

Locations: 🇨🇳
Sichuan Cancer Hospital & Institute, Chengdu, China
🇨🇳
Changhai Hospital, Shanghai, China
🇨🇳
Yantai Yuhuangding Hospital, Yantai, China

A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation

Phase 2

Not yet recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Camrelizumab
Drug: Apatinib

First Posted Date: 2024-08-09

Last Posted Date: 2024-08-09

Lead Sponsor: Zhujiang Hospital

Target Recruit Count: 38

Registration Number: NCT06546280

Locations: 🇨🇳
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China

SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma

Phase 2

Not yet recruiting

Conditions: Hepatocellular Carcinoma
SBRT
Immune Checkpoint Blockade
Tyrosine Kinase Inhibitor

Interventions: Drug: adbelimumab
Procedure: SBRT
Drug: apatinib

First Posted Date: 2024-08-06

Last Posted Date: 2024-08-06

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 80

Registration Number: NCT06538935

A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors

Phase 2

Not yet recruiting

Conditions: Solid Tumor

Interventions: Drug: Adebrelimab
Drug: Apatinib
Procedure: microwave ablation

First Posted Date: 2024-08-05

Last Posted Date: 2024-08-05

Lead Sponsor: Beidahuang Industry Group General Hospital

Target Recruit Count: 60

Registration Number: NCT06537505

A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer

Recruiting

Conditions: RWS
Gastric Cancer
PD-1 Immunotherapy

Interventions: Drug: Camrelizumab
Drug: apatinib
Drug: chemotherapy

First Posted Date: 2024-07-03

Last Posted Date: 2024-07-03

Lead Sponsor: Changzhi People's Hospital Affiliated to Changzhi Medical College

Target Recruit Count: 504

Registration Number: NCT06485271

Locations: 🇨🇳
Changzhi People's Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Phase 2

Recruiting

Conditions: Locally Advanced Thyroid Gland Carcinoma

Interventions: Drug: Anlotinib
Drug: Lenvatinib
Drug: Sorafenib
Drug: Donafenib
Drug: Everolimus
Drug: Apatinib
Drug: Dabrafenib + Trametinib
Drug: Cabozantinib
Drug: Vandetanib
Drug: Entrectinib
Drug: Pralsetinib
Drug: Larotrectinib

First Posted Date: 2024-07-01

Last Posted Date: 2024-12-05

Lead Sponsor: West China Hospital

Target Recruit Count: 75

Registration Number: NCT06482086

Locations: 🇨🇳
West China hospital, Chengdu, Sichuan, China

Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.

Phase 2

Not yet recruiting

Conditions: Esophageal Cancer

Interventions: Drug: Adebrelimab
Drug: Apatinib
Drug: Investigator chosen chemotherapy (ICC)
Radiation: Radiotherapy

First Posted Date: 2024-06-18

Last Posted Date: 2024-06-18

Lead Sponsor: The First Affiliated Hospital of Henan University of Science and Technology

Target Recruit Count: 54

Registration Number: NCT06464614

Locations: 🇨🇳
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

Phase 3

Recruiting

Conditions: HR+/HER2- Breast Cancer
Advanced Breast Cancer

Interventions: Drug: Apatinib
Drug: CDK4/6 Inhibitor
Drug: Aromatase inhibitor and Fulvestrant

First Posted Date: 2024-06-07

Last Posted Date: 2024-06-07

Lead Sponsor: Fudan University

Target Recruit Count: 184

Registration Number: NCT06447623

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis

Phase 2

Recruiting

Conditions: HER2-negative Breast Cancer Brain Metastases

Interventions: Drug: Adebrelimab
Drug: Apatinib
Drug: Etoposide

First Posted Date: 2024-05-17

Last Posted Date: 2024-12-10

Lead Sponsor: Beijing 302 Hospital

Target Recruit Count: 30

Registration Number: NCT06418594

Locations: 🇨🇳
The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy